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Basement membranes are heterogeneous, highly specialized,
electron-dense structures constructed from components of
extracellular matrix proteins 20 to 200 nm in width. They
provide anchorage for adjacent cells as well as stimuli for cell
differentiation, cell migration, and cell phenotype. These func-
tions provide basement membranes with an important role in
embryonic development and tissue repair. Basement mem-
branes are responsible for tissue compartmentalization and the
maintenance of tissue architecture. In addition, they are barri-
ers for the filtration of macromolecules. This latter function is
particularly apparent for the glomerular basement membrane
(GBM), which serves as the filtration barrier between the lumen
of the glomerular capillaries and the Bowman's space within the
renal glomerulus. Basement membranes are normally produced
and deposited by adjacent cells which then remain anchored to
the extracellular matrix via interactions with specific cellular
receptors [1—51.
In contrast to most basement membranes, the GBM is a
fusion product of two basement membranes produced by endo-
thelial and epithelial cells (podocytes). This special construc-
tion is responsible for the typical laminated structure of GBM,
which possesses a rather thick, duplicated lamina densa sand-
wiched between two external laminae rara. A similar architec-
ture is also observed within the alveolar and the placental
villous basement membranes. In addition, the GBM lacks a
lamina reticularis, which is found between most other basement
membranes and the surrounding connective tissue. Further-
more, the GBM is directly exposed to plasma proteins because
of fenestrations within the endothelial cell layer. It is also in
close contact with the mesangial matrix, which is a basement
membrane-like intraglomerular matrix produced by mesangial
cells. The mesangial cells are believed to play a role in the
regulation of intraglomerular hemodynamics, and may also play
a major role in the maintenance of chronic inflammatory pro-
cesses within the glornerulus [1, 6].
The biochemical composition of basement membrane and the
characterization of its components has been studied extensively
during the last decade by using appropriate models such as the
Englebreth-HoIm-Swarm (EHS) mouse tumor [7]. This model
provides improved understanding of the structure and macro-
molecular organization of all basement membranes including
the GBM. The present article will review the properties of the
major basement membrane proteins involved in GBM forma-
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tion and discuss their possible role in some basement mem-
brane-related diseases.
Collagen IV
The GBM is highly insoluble and shows a distinct mechanical
stability. These properties are thought to be due to a network of
collagen IV molecules, which is the collagen characteristically
found in basement membranes [8]. Individual collagen IV
monomers have a characteristic shape. They consist of a 390
nm long triple helical rod, which is terminated at its C-terminal
end by a globular NC! domain. The N-terminus is referred to as
the 7S domain. This third structural domain plays a unique role
in oligomer formation. Based on data from the EHS-tumor
matrix, the collagen IV molecule was originally believed to be a
heterodimer constructed from two genetically distinct alpha-
chains, [alphal(IV)]2 and (alpha2(IV))1. The existence of these
two classical chains was confirmed by cloning and complete
sequence analysis [9—15]. However, studies on the structure of
bovine and human GBM demonstrated that these particular
basement membranes were far more complex than that identi-
fied from the EHS-tumor matrix. Both bovine and human
basement membranes contain two novel chains, alpha3 and
alpha4, in addition to the two classical chains (alphal(IV) and
alpha2(IV)) [16—18], A clone encoding 471 residues of the
bovine alpha3(IV) chain was recently described [19]. Moreover,
a further chain named alpha5(IV) was recently cloned on the
basis of similarities with other type IV collagens [20, 21].
The polypeptide chains of collagen IV differ from the alpha
chains of the fiber forming collagens (types I,II,III,V), in that
they contain interruptions in their Gly-X-Y repeats of their
collageneous domain. In addition, their N-terminal and C-ter-
minal domains are not proteolytically processed during biosyn-
thesis. In human collagen IV there are 21 interruptions in the
alphal(IV), 23 in the alpha2(IV) chain, and 22 in the alpha5(IV)
chain. The interruptions are evenly distributed along the helix
and parallel each other in most instances. Similar interruptions
also exist in the alpha3(IV) chain. These interruptions endow
the collagen IV triple helix with a high degree of flexibility
compared to fiber-forming collagens. Moreover, they provide
sites for proteolytic digestion [9, 12, 15, 21].
A high degree of sequence similarity between the NC1
segments was found, not only for the alphal(IV) and alpha2(IV)
chain, but also for the newly appreciated alpha(IV) chains. The
alpha5(IV) chain appears to be more related to alphal(IV) than
to the alpha2(IV) chain. For the NCI domain, an 83% identity
was identified between alpha5(IV) and alphal(IV), in contrast
to an identity of 63% between alpha5(IV) and alpha2(IV) [21].
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Furthermore, the NC! domain of the bovine alpha3(IV) chain
shows an overall similarity of 71%, 61%, and 70% with the
human alphal(IV), alpha2(IV), and alpha5(IV) NC1 domain,
respectively [19]. The alphal(IV) and alpha2(IV) segments of
NC1 both show distinct internal repeats, with each having six
cysteine residues in invariant positions. Each set of cysteine
residues forms three disulfide bonds, thus generating a symmet-
rical folding pattern into two subdomains within the NCI
segments [22].
The terminal domains, NC! and 7S, allow the collagen IV
monomers to interact with each other during self assembly. The
7S domains associate with one another to form tetramers by
lateral alignment over a 30 nm distance alternating in a parallel
and an antiparal!el fashion. Dimers are generated by interac-
tions between the globular NC! domains. Both sites of interac-
tion become stabilized by covalent cross linking with inter-
chain disulfide bonds. They can be isolated as defined fragments
from basement membranes by digestion with bacterial collage-
nase. Further non-reducible cross links also exist [23—27]. The
NCI domain was shown to consist only of monomeric and
dimeric chain segments in non-covalent association. The dimers
are believed to be constructed of disulfide bonds of monomers
originating from two different collagen IV molecules. While
dimers have the potential to reconstitute into intact globular
structures, such structures cannot be achieved by combining
monomeric segments [26]. An additional function of the NC!
domain may be the control of self-association and folding of the
triple-helical domain [28]. The assembly of collagen IV mono-
mers into a complex, supra-molecular structure appears to
begin at the 7S domain, as indicated by studies with collagen IV
monomers from cell cu!tures [29]. Others have suggested that
COOH-terminal dimer formation occurs first [24]. These dis-
crepancies may indicate that the steps of assembly could
proceed by several paths in parallel (Fig. 1).
One of the major functions of collagen IV is believed to be the
formation of supportive structures constructed by an assembly
of collagen IV monomers to large supramolecular aggregates.
One early structural proposal suggested that collagen IV mole-
cules associate into an unlimited network by the alternating use
of 7S and NC! cross linking domains [23]. However, further
investigations showed that the collagen IV network is far more
complex. The network includes lateral interactions along the
Table
mem
1. Interactions and binding abilities of different basement
brane proteins (C-IV = collagen IV, PG = proteoglycan)
Cells Ca2 Laminin Nidogen PG C-IV BM-40 BM-90
C-IV + ? + + + + + ?
Laminin + + + + + + — +
PG + ? + ? + + — +
Nidogen + + + + + + —
BM-40 — + — ? — + —
BM-90 ? + + ? ? ? ?
triple helix and additional binding of further NC1 segments into
triple helical domains [24, 25]. Thus, an irregular network may
be formed in situ, as was recently shown by electron micros-
copy of partially extracted basement membranes [30]. In addi-
tion, collagen IV has also the ability to bind laminin, proteo-
glycan, nidogen, and cells themselves (Table 1) [4].
The genes for the different alpha-chains of collagen IV have
been localized on different chromosomes. The genes for human
alpha 1 (IV) and alpha2(IV) were found on chromosome 13. They
are located on opposite strands and share a 120-bp promoter
region [31, 32]. The gene for alpha5(IV) was localized on the
X-chromosome [20, 21]. The gene for the alpha3(IV) and the
alpha4(IV) chain (S. Reeders, personal communication) was
recently identified on chromosome 2 [33, see Turner et a!, this
volume].
Laminin
Laminin is an ubiquitous, non-collagenous basement mem-
brane component with a unique, cruciform structure which has
distinct, cell binding properties (Fig. l)[34, 35]. A more detailed
discussion of laminin is available in a recent comprehensive
review [36]. The most commonly studied isoform of laminin,
murine EHS laminin, has a molecular weight of 900 kDa and
consists of three polypeptide chains, A (400 kDa), B!, and B2
(each 220 kDa), which are linked together by disulfide bonds.
The molecule is composed of three short arms (37 nm) and one
long arm (77 nm). The short arms consist of two globular
domains connected by rod-like elements; the long arm appears
as a long rod which also terminates in a globular domain. While
each N-terminus of the polypeptide chains forms one short arm,
all three chains are joined by disulfide bonds to form the long
Monomer
7S
IIIIiII112 Fig. 1. Model of type IV collagen and its twomodes of association. The bar indicates 100nm (reproduced with permission from R.Timpl, Ref. 3).
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arm. However, the C-terminal segment of the long A chain
alone forms the distal globular domain of the long arm (Fig. 2).
Laminin chains from several species have been cloned and
sequenced. Other laminin isoforms exist which have different
biologic activities [36, 37].
The genes for the different laminin chains have been localized
to the human chromosome 7 for B 1, chromosome 1 for B2, and
chromosome 18 for the A-chain [38—411. In some cell lines, the
synthesis of the three laminin chains is conducted in a coordi-
nated fashion, suggesting common regulatory mechanisms.
Other studies have shown that this is not always the case. In
several tissues, very little or no laminin A-chain polypeptide
has been found, although B chains could be identified. During
embryogenesis, laminin appears as the first extracellular matrix
protein. The A chain especially seems to play an important role
in cell polarization, since A-chain-specific antibodies block the
polarization of epithelia in transfiltered kidney organ cultures
[42, 43].
Laminin has the ability to polymerize in vitro through inter-
actions between the terminal globular domains of the molecule.
Polymerization occurs in the presence of calcium. It is not
known whether or not calcium plays a role in laminin polymer-
ization in vitro [36]. The molecule also has the ability to bind to
collagen IV [44, 45]. However, in vitro the binding of laminin to
collagen IV may be more effectively mediated by nidogen. In
addition, laminin also has binding potential for heparan sulfate
proteoglycan. The major binding site was mapped to fragment
E3, which corresponds to the C-terminal segment of the
A-chain [46, 47]. This segment contains several amino acid
residues, which may be involved in heparin binding (Table 1).
The major functions of laminin involve its ability to interact
with cells and to modulate cell behavior. These functions
include cell adhesion, cell polarization, cell spreading, cell
migration, cell differentiation, induction of neurite outgrowth
B2, NH2 and possibly other functions as well. To study the biologic
functions of the molecule in more detail, proteolytic fragments
were produced (fragment 1-8). While many of the activities of
laminin disappeared on separation of the various proteolytic
components, some fragments remained of considerable interest
in that they retained their activity. The fragment 1 (P1), which
consists of the three short arms, bears an RGD sequence which
usually is cryptic or latent and becomes exposed after protease
digestion [48]. P1 possesses cell binding activities. Fragment E3
is also involved in cell binding and cell polarization [49]. The E8
fragment represents the lower 35 nm of the long arm and is
involved in cell attachment, cell polarization, neurite outgrowth
and cell locomotion [50—52, see also the contribution by Good-
man in this volume]. Moreover, laminin may also possess
growth-promoting activities (El-fragment), which in some situ-
ations was comparable to that produced by EGF [53] (Fig. 2).
The binding of cells to laminin is mediated by integrin
receptors. Depending on the cell type investigated, intact
EHS-laminin binds to five 31 integrins: alphal/31, alpha2f3l,
alpha3/3l, alpha6/31, and alpha7f3l. Alphalf3l binds to the El
region, alpha3/3l, alpha6/31, and alpha7/3l bind to E8. The
binding site of alpha2f3l is not well characterized. Of these
various receptors, alpha6f3l seems to be the major laminin
receptor [54]. The reasons for the multiple E8 receptors are not
well understood. In addition to the binding via integrins, the
binding of laminin to cells may also include interactions with
phospholipids and heparan sulfate.
Nidogen/entactin
Both molecules were first isolated as distinct proteins [55,
56]. However, cloning data showed that they were identical
[57—59]. Nidogen has a molecular weight of 148 kDa. It consists
of 1217 amino acid residues and about 5% carbohydrate.
Electron microscopy after rotary shadowing demonstrated a
molecule containing two globular domains at the N-terminus
and C-terminus with an estimated mass of 38 kDa and 85 kDa
respectively, which are connected by a 17 nm-long stalk.
However, the complete polypeptide sequence, which has been
deduced from eDNA cloning, differs in that three globular
domains are present (Gl, G2, G3). The Gl and G2 domain
collapse after isolation with guanidine-HC1. The larger N-ter-
minal Gl domain is linked by EGF-like repeats to the G2
domain (Fig. 2). These domains are connected to the C-terminal
G3 domain by a rod domain, which also contains several
EGF-like repeats. The globular domains are easily cleaved by
endogeneous and exogeneous proteases, yielding fragments of




















Fig. 2. Structural model of the laminin-nidogen complex. The cruci-
form structure of laminin is formed by the BI, B2, and A chains.
Nidogen is attached to the fragment P1 as shown on the cartoon. The
locations of the proteolytically generated fragments P1, E3, E4, and E8,
as well as their appropriate functions are indicated (provided by R.
Timpl).
Weber: Basement membrane proteins 623
nidogen was considered to be important for basement mem-
brane remodelling [reviewed in 60]. Recently, antibodies to the
molecule were detected in several forms of human glomerulo-
nephritis [61, 621.
The laminin-nidogen complex
Nidogen forms tight, non-covalent complexes with laminin
[63]. These laminin-nidogen complexes can be extracted from
basement membranes using physiologic buffers containing
EDTA. Studies with mouse laminin-nidogen complexes dem-
onstrated an equimolar ratio of both components (Fig. 2). The
complex is formed by attachment of nidogen by its C-terminal
globular domains to the inner rod-like segment of one short arm
of laminin (fragment 1). Binding of nidogen is accompanied by
an increased protein resistance of nidogen. Nidogen also binds
to collagen IV. but the binding forces are weaker compared to
laminin [641. The interaction with collagen IV involves the
C-terminal globular G2 domain of nidogen and the triple-helical
sites in collagen IV, which are also involved in laminin-binding.
Thus, nidogen may act as a major bridging protein for several
matrix constituents (Table 1).
In addition, nidogen may also support cell adhesion or modify
the cell-binding abilities of laminin. The RGD integrin recogni-
tion sequence has been identified in one of the EGF-like repeats
of the stalk region [57]. Morphologic studies localized nidogen
and the short arms of laminin to the boundary between the
lamina rara and the lamina densa, indicating that the binding
sites may not be in direct contact with the cells in tissue [65].
However, the cell binding ability of nidogen may play a role in
membrane synthesis and tissue remodeling, as for example in
embryogenesis, wound healing, and metastastic tumors.
Proteoglycans
The presence of polyanionic proteoglycans in basement
membranes was initially suggested by electron microscopy
using cationic probes, and was subsequently identified in stud-
ies of GBM [66—68]. The polyanionic sites can be destroyed by
heparitinase, indicating that they contain heparan sulfate
chains. These heparan sulfate chains are bound to protein
cores. Conflicting results were reported concerning the size and
composition of the proteoglycans, indicating that they may
differ in the size of the protein core, as well as in the heparan
sulfate side chains. Studies from the EHS tumor matrix indi-
cated the existence of at least two forms, a low density form
with a large protein core and a high density form with a small
protein core, and also smaller heparin sulfate side chains (Fig.
3). The low density form (600 kDa) possesses a 80-nm-long
multidomain protein core (500 kDa), which terminates at one
end into three heparan sulfate chains [69, 70]. A heparan sulfate
proteoglycan with a large protein core was isolated from GBM
[71, 72]. The data of the high-density form (130 kDa) indicate a
star-like structure with four heparin sulfate side chains being
attached to a small protein core (5 to 18 kDa). This proteoglycan
was also found in GBM [73, 74]. It is currently unclear whether
the diversity of the proteoglycans may arise from proteolytic
degradation of the major low-density form or if the two forms
represent different gene products. The proteoglycans are
strongly bound within the basement membrane and are possibly
clustered by self assembly.
One function of the proteoglycans may be the charge-selec-
Fig. 3. Basement membrane heparan sufate proteoglycans. The low
density form is shown on the left side, the high density form is given on
the right. The bar indicates 100 nm. The protein cores are shown in
black, the heparan side chains in dashed lines (Adapted from Paulsson
et al, Ref. 70, used with permission).
tive control of filtration through basement membranes. In
addition, weak interactions with other basement membrane
components, including laminin and collagen IV have been
described. Some proteoglycans may be involved in the control
of serine protease activity which may be important for remod-
elling of basement membranes [75]. Furthermore, fibroblast
growth factor or TGF-f3 may be deposited in and stored by
proteoglycans. These mediators may act as locally fixed cyto-
kines and may be very important in physiologic or pathophys-
iologic processes [76, 77, see also Border et a!, this volume].
BM-40/osteonectin/SPARC
This 40 kDa protein can be extracted from the EHS tumor
matrix and from basement membranes by chelating agents
together with the laminin-nidogen complex [78, 79]. Compari-
son of sequence data showed identity of BM-40 with the
endoderm protein SPARC and osteocalcin, which initially was
considered to be bone-specific [80—83]. Although BM-40 is
secreted by cells which synthesize other basement membrane
proteins and is present in comparable amounts to laminin and
nidogen, immunofluorescence staining failed to demonstrate the
molecule in several basement membranes [78]. The antigenic
determinants may therefore be masked in a way similar to those
of collagen II in hyaline cartilage. Similar to laminin, BM-40 has
distinct calcium-binding properties [84]. The general function of
this widespread molecule is not known. It was suggested that it
may prevent calcification of basement membranes.
Other basement membrane proteins
Considerable progress has been made concerning the struc-
tural and functional characterization of the major basement
membrane constituents. However, several other proteins have
been identified. Some of these proteins have a restricted distri-
bution, such as amyloid P and acetylcholinesterase [3, 4]. An
additional group of proteins are major components of serum as
well as being present in the extracellular matrix, such as
fibronectin, vitronectin, von Willebrand factor, and certain
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[85, 86]. BM-90, a further calcium-binding glycoprotein recently
isolated from the EHS tumor matrix, also belongs to this group
[87]. All of these different proteins may have specific functions
when present. Other components may be expressed only tran-
siently during development. In addition, proteases [88], growth
factors and other regulatory components may be deposited
within the meshwork of the structural proteins [77, see also AB
Roberts et al, in this volume]. The functional role of all these
components and of other unidentified polypeptides is currently
only incompletely defined and requires further investigation.
General molecular architecture
A three dimensional network of type IV collagen appears to
form the basic superstructure upon which the other components
of the diverse basement membranes are attached [23, 30]. In
transmission electron microscopy the lamina densa is charac-
terized by a network of 3 to 4 nm cords with 8 to 14 nm
intercordal spaces. The cords are centered by collagen IV
surrounded by laminin, and are further associated by heparan
sulfate proteoglycans which form double tracks [891. The lam-
mae rara have a more amorphous appearance. The latter may
show a periodic arrangement of heparan sulfate proteoglycans,
as shown by studies with cationic dyes [68]. In addition, since
basement membranes are heterogeneous, the final architecture
may also be influenced by the concentrations of the individual
components during synthesis, degradation, and remodelling
[90].
Basement membranes in acquired and inherited diseases
In diabetic glomerular disease, a characteristic expansion of
glomerular basement membrane and mesangial matrix is ob-
served. Analysis of human glomerular basement membranes
indicated an increase in type IV collagen and a reduction in the
content of laminin and heparan sulfate proteoglycan [91]. Non-
enzymatic protein glycosylation may play an important role in
the development of diabetic nephropathy and microangiopathy
[92, 93]. It was suggested that an accumulation of glycosylated
protein modifications in the basement membranes may result in
decreased association and deleterious structural and functional
changes. In addition, the reduction in the proteoglycan content,
which was calculated to be 33% for the human diabetic glomer-
ular basement membrane [94], was also considered to be
responsible for the nephrotic range proteinuria seen in many
patients with diabetic glomerulopathy. Interestingly, glycosy-
lated laminin loses its ability to bind heparan in vitro, indicating
that non-enzymatic glycosylation may also contribute to the
decrease in proteoglycans [95]. It remains to be determined
whether or not this reduction in the amount of proteoglycans
may also influence the binding of TGFI3 [77].
The anionic basement membrane proteoglycans may also
serve as preferential attachment sites for cationic antigens or
cationic antibodies. Following the trapping of the molecules
along the glomerular basement membrane, in situ immune
deposits may be formed after binding of the corresponding
antibodies (or antigens). Evidence for this possibility was first
derived from animal experiments [96—98]. In addition, the
cationic histones are also fixed along the glomerular basement
membrane, thereby allowing double-stranded DNA (dsDNA) to
bind to its nucleoprotein. Anti-dsDNA antibodies may then
bind to this in situ deposits. This observation suggests that in
situ immune complex formation may also play a role in the
pathogenesis of lupus nephritis [99].
Antiglomerular basement membrane (anti-GBM) antibodies
play a pathogenetic role in Goodpasture's syndrome and anti-
GBM mediated glomerulonephritis. The epitopes for these
autoantibodies are located on the globular NC I domain of type
IV collagen [100—103]. The hexameric globule dissociates revis-
ibly into monomers and dimers when exposed to denaturating
agents or acid pH. Upon dissociation, the number of accessible
epitopes increases 20- to 50-fold, which may play a role in the
pathogenesis of the autoimmune disease [26, 104, 105]. In
addition, the main reactivity of the anti-NC1(IV) antibodies was
shown to be directed against the C-terminus of the novel
alpha3(IV) chain [16, 17, 106, reviewed in 1071. This chain
displays a restricted distribution. Antibodies against the
alpha3(IV) chain localize to basement membranes of glomerular
capillary loops, distal tubules, alveolar capillaries, and to vari-
ous structures of the eye. Anti-alpha3(IV) antibodies, however,
do not bind to mesangial matrix, or basement membranes of
placenta, liver, spleen, and skin [108, 109]. We have isolated
NC1 globules from basement membranes of human kidney
glomeruli, kidney tubuli, lung alveoli, small intestine, and
placenta. Attempts to estimate the amount of available Good-
pasture epitopes in these different preparations showed that
Nd from kidney GBM and lung alveolar basement membrane
contained comparable amounts of epitopes. In contrast, NC!
from tubular basement membrane possessed only 20% of Good-
pasture epitopes. Further, NC1 from small intestine or placenta
basement membranes had only minimal or no epitopes. Addi-
tional studies indicated that this heterogeneous reactivity par-
allels the occurrance of the alpha3(IV) collagen chain (Fig. 4).
This heterogeneity in the distribution of the alpha3(IV) chain
may possibly explain the preferential involvement of the lungs
and the kidneys in this autoimmune disease [110].
X-linked Alport syndrome appears to result from mutations
in the COL4A5 gene coding for the newly described alpha5(IV)
chain. This form of hereditary nephritis is characterized by
non-immune thickening, thinning, and splitting of the GBM.
Phenotypic expression of the disease in different kindreds
varies with respect to the age of onset of end-stage renal failure,
the severity of associated deafness, and the presence of other
nonrenal abnormalities, such as anterior lenitconus and retinal
abnormalities [Ill, 112]. Studies with anti-NC1(IV) antibodies
indicated alterations or absence of a type IV collagen alpha-
chain [113, 114]. In addition, patients with Alport syndrome
may develop anti-GBM antibodies and glomerulonephritis after
renal transplantation, which also indicates structural abnormal-
ities in the NCI domain of type IV collagen [1151. The COL4A5
gene has been assigned to the Xq22 locus, a region to which the
Alport syndrome gene has also been assigned [20, 116]. Re-
cently, three different structural aberrations were found in the
COL4A5 gene of 18 Alport syndrome kindreds by conventional
Southern blot analysis, which supports the notion that muta-
tions in this gene account for X-linked Alport syndrome [117].
In addition, by analyzing 20 different Alport syndrome kindreds
from Germany, we also identified two different deletions in the
COL4A5 gene with the same technique (Fig. 5) [118]. More
sensitive test systems are necessary to analyze whether or not
only a portion, or possibly all X-linked Alport syndromes have
mutations in this gene.
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Fig. 4. Immunoblot ofNd hexamers
isolated from glomerular (GBM), renal
tubular (TBM), alveolar (ABM), placental(PBM), and intestinal basement membranes
(IBM). The origin of the NCI hexamer is
indicated on the top. The lanes 1 show the
amidoblack staining of the blotted proteins.
The lanes 2 and 3 were incubated with
Goodpasture sera; lanes 4 and 5 were overlaid
with monoclonal antibodies to human
alphal(IV) (lane 4) or alpha3(IV) (lane 5).
Normal human control serum = lane 6. Note,
that Goodpasture sera show binding to dimers
but not to all monomers of the various NCI
preparations. Alpha3(IV) monomers and
dimers are only detectable in GBM-NCI and
ABM-NCI; a weak dimer staining is
detectable in TBM-NC1. In contrast, no
evidence for the alpha3(IV) chain is found in
IBM-NC! and in PBM-NCI [110].
Fig. 5. Model of the alpha5 chain of type IV
collagen and of the COL4A5 gene. The
deletions found in one of our Alport males
includes 14 exons from the 3' end of the gene
which would result in a lack of the complete
NCI domain and parts of the triple helix. The
deletion found in the second Alport male
involves the complete COL4A5 gene [118].
Antibodies to entactin/nidogen were recently reported to
occur in about 40% of patients with non-anti-GBM glomerulo-
nephritis [62]. The antibodies were found in various glomeru-
lonephritidies with granular immunofluorescence pattern. On
indirect immunofluorescerice the antibodies failed to stain nor-
mal kidneys. At the present time, the pathogenetic role of these
antibodies is not well defined.
Recently, it was found that the autoantibodies in acquired
epidermolysis bullosa bind to the C-terminal NC1 segment of
type VII collagen [119]. This collagen is constructed from three
identical alphal(VII) chains. The genuine protein is a procolla-
gen which has an N-terminal globular segment NC2 (30 kDa), a
triple helix (170 kDa), and a C-terminal globular domain NCI
(159 kDa). The molecule participates in the formation of an-
choring fibrils, which connect the lamina densa of the basement
membranes to the underlying stroma, and which are involved in
the attachment of cells to basement membranes. Such connec-
tions are disturbed in acquired epiderolysis bullosa, and result
in the severe and chronic blistering reaction. In addition, in
recessive dystrophic epidermolysis bullosa there is no detect-
able type VII collagen in the skin [120].
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